



Material Safety Data Sheet

12601 Twinbrook Parkway
Rockville, MD 20852 USA

Telephone calls: (301) 881-0666
8:00am - 5:00pm EST Mon. - Fri.

Responsible Party: Roger Williams

ATTENTION !

USP Reference Standards are sold for chemical test and assay purposes only, and NOT for human consumption. The information contained herein is applicable solely to the chemical substance when used as a USP Reference Standard and does not necessarily relate to any other use of the substance described, (i.e. at different concentrations, in drug dosage forms, or in bulk quantities). USP Reference Standards are intended for use by persons having technical skill and at their own discretion and risk. This information has been developed by USP staff from sources considered reliable but has not been independently verified by the USP. Therefore, the USP Convention cannot guarantee the accuracy of the information in these sources nor should the statements contained herein be considered an official expression. NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE is made with respect to the information contained herein.

RIFAMPIN ✓

Catalog Number: 60400

Package Size: 300 mg

Revision Date: October 24, 2000

SECTION 1 - IDENTIFICATION

Common Name: Rifampin
Synonym: Rifampicin; Rifamycin AMP
Chemical Name: Rifamycin, 3-[[[4-methyl-1-piperazinyl]imino]methyl]-
CAS Number: 13292-46-1
Chemical Family: A Macrolide antibiotic
Therapeutic Category: Antibacterial

DATE: 12/13/00
REVIEWED BY: L. FERRELL
COMMENT: CAS 13292-46-1
RATING: 2

Formula: C₄₃H₅₈N₄O₁₂
RTECS Number: VJ7000000

SECTION 2 - INGREDIENT INFORMATION

Principle Components	Percent	Exposure Limits
Rifampin	Pure Material	n/f

SECTION 3 - HEALTH HAZARD INFORMATION

Usual Adult Dose: The usual oral adult dose of rifampin is up to but not exceeding 600 mg daily.

Adverse Effects: Rifampin is usually well-tolerated and adverse effects are more common during intermittent use. Adverse effects may include diarrhea; stomach cramps; reddish-orange to reddish-brown discoloration of urine, feces, saliva, sweat, or tears; chills; difficulty breathing; dizziness; fever; headache; muscle and bone pain; shivering; itching, redness, or rash of the skin; and sore mouth or tongue. Possible allergic reaction to material if inhaled, ingested or in contact with skin.

Overdose Effects: Symptoms of overdose may include mental changes, swelling around the eyes or the whole face, itching over the whole body, and red-orange discoloration of the skin, mucous membranes, and whites of the eyes.

Acute: Possible eye, skin, gastrointestinal and/or respiratory tract irritation.

Chronic: Possible hypersensitization.

Inhalation: May cause irritation. Remove to fresh air.

RIFAMPIN

Catalog Number: 60400

Package Size: 300 mg

Revision Date:

October 24, 2000

Eye: May cause irritation. Flush with copious quantities of tepid water for 15 minutes.

Skin: May cause irritation and contact dermatitis. Flush with copious quantities of water.

Ingestion: May cause irritation. Flush out mouth with water. This material is well absorbed from the gastrointestinal tract.

**Medical Conditions
Aggravated by Exposure:**

Hypersensitivity to material, history of or active alcoholism, and impaired liver function.

Cross Sensitivity: Persons sensitive to any of the rifamycins may be sensitive to this material also.

Pregnancy Comments:

Adequate and well-controlled pregnancy studies in humans have not been done. Rifampin has rarely caused postnatal hemorrhage in the mother and infant following administration during the last few weeks of pregnancy. Studies in rodents have shown that rifampin given in extremely large doses causes abnormal development of the fetus, primarily cleft palate and spina bifida; similar studies in rabbits caused abnormal bone formation and embryo death.

Pregnancy Category: C

SECTION 4 - FIRST AID MEASURES

General: Remove from exposure. Remove contaminated clothing. Persons developing serious hypersensitivity (anaphylactic) reactions must receive immediate medical attention. If person is not breathing give artificial respiration. If breathing is difficult give oxygen. Obtain medical attention.

Overdose Treatment:

Treatment of overdose with rifampin is primarily supportive and may include the following:

1. To decrease absorption, empty the stomach using syrup of ipecac or gastric lavage.
2. Administer an activated charcoal slurry to help absorb residual rifampin in the gastrointestinal tract.
3. Antiemetic medication may be required to control severe nausea and vomiting.
4. Active diuresis (with measured input and output) will help promote excretion of the drug.
5. Hemodialysis may be of value in some patients. [USP DI 20th ed. 2000; PDR 2000]

SECTION 5 - TOXICOLOGICAL INFORMATION

Oral Rat: LD50: 1570 mg/kg

Oral Mouse: LD50: 500 mg/kg

Irritancy Data: n/f

Target Organ(s): n/f

Listed as a Carcinogen? NTP: No IARC: No OSHA: No

Other: An increase in the incidence of hepatomas in female mice (of a strain known to be particularly susceptible to the spontaneous development of hepatomas) was observed when rifampin was administered in doses 2 to 10 times the average daily human dose for one

SECTION 6 - FIREFIGHTING MEASURES

Flash Point: n/f

Upper Flammable Limit: n/f

Auto-Ignition Temperature: 520° C

Lower Flammable Limit: n/f

Extinguisher Media: Water spray, dry chemical, carbon dioxide or foam as appropriate for surrounding fire and materials.

Fire and Explosion Hazards: This material is assumed to be combustible. As with all dry powders it is advisable to ground mechanical equipment in contact with dry material to dissipate the potential buildup of static electricity.

Firefighting Procedures: As with all fires, evacuate personnel to a safe area. Firefighters should use self-contained breathing

equipment and protective clothing.

SECTION 7 - PHYSICAL HAZARDS

- Conditions to Avoid:** Avoid exposure to light, heat, air (oxygen), and moisture.
- Incompatibilities:** n/f
- Decomposition Products:** When heated to decomposition material emits toxic fumes of NO_x. Emits toxic fumes under fire conditions.
- Stable?** Yes **Hazardous Polymerization?** No

SECTION 8 - HANDLING / SPILL / DISPOSAL MEASURES

- Handling:** As a general rule, when handling USP Reference Standards avoid all contact and inhalation of dust, mists, and/or vapors associated with the material. Wash thoroughly after handling.
- Storage:** Store in tight, light-resistant container as defined in the USP-NF. This material should be handled and stored per label instructions to ensure product integrity. Avoid exposure to oxygen. Store in a refrigerator.
- Spill Response:** Wear approved respiratory protection, chemically compatible gloves and protective clothing. Wipe up spillage or collect spillage using a high efficiency vacuum cleaner. Avoid breathing dust. Place spillage in appropriately labelled container for disposal. Wash spill site.
- Disposal:** Dispose of waste in accordance with all applicable Federal, State and local laws.

SECTION 9 - EXPOSURE CONTROLS / PERSONAL PROTECTION

- Respiratory Protection:** When working with small quantities in a well-ventilated area, respiratory protection may not be required. The use of an approved dust mask is recommended.
- Ventilation:** No special ventilation requirements.
- Gloves:** Rubber
- Eye Protection:** Safety Glasses
- Protective Clothing:** Protect exposed skin.

SECTION 10 - PHYSICAL AND CHEMICAL PROPERTIES

NOTE: The data reported below is general information, and is not specific to the USP Reference Standard Lot provided!

- Appearance and Odor:** Reddish-brown crystalline powder; odorless or practically odorless.
- Melting Point:** 183 - 188° C (decomposes)
- Solubility in Water:** Very slightly soluble **Vapor Density:** n/f
- Boiling Point:** n/f **Evaporation Rate:** n/f
- Specific Gravity:** n/f **Reactivity in Water:** n/f
- Vapor Pressure:** n/f **% Volatile by Volume:** n/f